Literature DB >> 25896248

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

Joost H van den Berg1,2, Raquel Gomez-Eerland1, Bart van de Wiel3, Lenie Hulshoff4, Daan van den Broek5, Adriaan Bins6, Hanno L Tan7, Jane V Harper8, Namir J Hassan8, Bent K Jakobsen8, Annelies Jorritsma1, Christian U Blank1,6, Ton N M Schumacher1, John B A G Haanen1,6.   

Abstract

Here, we describe a fatal serious adverse event observed in a patient infused with autologous T-cell receptor (TCR) transduced T cells. This TCR, originally obtained from a melanoma patient, recognizes the well-described HLA-A*0201 restricted 26-35 epitope of MART-1, and was not affinity enhanced. Patient 1 with metastatic melanoma experienced a cerebral hemorrhage, epileptic seizures, and a witnessed cardiac arrest 6 days after cell infusion. Three days later, the patient died from multiple organ failure and irreversible neurologic damage. After T-cell infusion, levels of IL-6, IFN-γ, C-reactive protein (CRP), and procalcitonin increased to extreme levels, indicative of a cytokine release syndrome or T-cell-mediated inflammatory response. Infused T cells could be recovered from blood, broncho-alveolar lavage, ascites, and after autopsy from tumor sites and heart tissue. High levels of NT-proBNP indicate semi-acute heart failure. No cross reactivity of the modified T cells toward a beating cardiomyocyte culture was observed. Together, these observations suggest that high levels of inflammatory cytokines alone or in combination with semi-acute heart failure and epileptic seizure may have contributed substantially to the occurrence of the acute and lethal event. Protocol modifications to limit the risk of T-cell activation-induced toxicity are discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896248      PMCID: PMC4817886          DOI: 10.1038/mt.2015.60

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  39 in total

1.  Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.

Authors:  Pierre-Yves Dietrich; Frédérique-Anne Le Gal; Valérie Dutoit; Mikäel J Pittet; Lydie Trautman; Alfred Zippelius; Isabelle Cognet; Valérie Widmer; Paul R Walker; Olivier Michielin; Philippe Guillaume; Thierry Connerotte; Francine Jotereau; Pierre G Coulie; Pedro Romero; Jean-Charles Cerottini; Marc Bonneville; Danila Valmori
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

2.  Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Authors:  Thinle Chodon; Begoña Comin-Anduix; Bartosz Chmielowski; Richard C Koya; Zhongqi Wu; Martin Auerbach; Charles Ng; Earl Avramis; Elizabeth Seja; Arturo Villanueva; Tara A McCannel; Akira Ishiyama; Johannes Czernin; Caius G Radu; Xiaoyan Wang; David W Gjertson; Alistair J Cochran; Kenneth Cornetta; Deborah J L Wong; Paula Kaplan-Lefko; Omid Hamid; Wolfram Samlowski; Peter A Cohen; Gregory A Daniels; Bijay Mukherji; Lili Yang; Jerome A Zack; Donald B Kohn; James R Heath; John A Glaspy; Owen N Witte; David Baltimore; James S Economou; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

3.  Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Authors:  Raquel Gomez-Eerland; Bastiaan Nuijen; Bianca Heemskerk; Nienke van Rooij; Joost H van den Berg; Jos H Beijnen; Wolfgang Uckert; Pia Kvistborg; Ton N Schumacher; John B A G Haanen; Annelies Jorritsma
Journal:  Hum Gene Ther Methods       Date:  2014-09-22       Impact factor: 2.396

4.  Early seizures in intracerebral hemorrhage: incidence, associated factors, and outcome.

Authors:  V De Herdt; F Dumont; H Hénon; P Derambure; K Vonck; D Leys; C Cordonnier
Journal:  Neurology       Date:  2011-10-05       Impact factor: 9.910

5.  Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.

Authors:  Danila Valmori; Valerie Dutoit; Valerie Schnuriger; Anne-Lise Quiquerez; Mikaël J Pittet; Philippe Guillaume; Verena Rubio-Godoy; Paul R Walker; Donata Rimoldi; Danielle Liénard; Jean-Charles Cerottini; Pedro Romero; Pierre-Yves Dietrich
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

6.  Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.

Authors:  J Weber; J C Yang; S L Topalian; D R Parkinson; D S Schwartzentruber; S E Ettinghausen; H Gunn; A Mixon; H Kim; D Cole
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

7.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

8.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

9.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Authors:  Gerald P Linette; Edward A Stadtmauer; Marcela V Maus; Aaron P Rapoport; Bruce L Levine; Lyndsey Emery; Leslie Litzky; Adam Bagg; Beatriz M Carreno; Patrick J Cimino; Gwendolyn K Binder-Scholl; Dominic P Smethurst; Andrew B Gerry; Nick J Pumphrey; Alan D Bennett; Joanna E Brewer; Joseph Dukes; Jane Harper; Helen K Tayton-Martin; Bent K Jakobsen; Namir J Hassan; Michael Kalos; Carl H June
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

10.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

View more
  47 in total

Review 1.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 2.  Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.

Authors:  Paul Mayor; Kristen Starbuck; Emese Zsiros
Journal:  Gynecol Oncol       Date:  2018-05-24       Impact factor: 5.482

3.  Detection of ABCB5 tumour antigen-specific CD8+ T cells in melanoma patients and implications for immunotherapy.

Authors:  S Borchers; C Maβlo; C A Müller; A Tahedl; J Volkind; Y Nowak; V Umansky; J Esterlechner; M H Frank; C Ganss; M A Kluth; J Utikal
Journal:  Clin Exp Immunol       Date:  2017-10-24       Impact factor: 4.330

4.  Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Authors:  Scott R Walsh; Donald Bastin; Lan Chen; Andrew Nguyen; Christopher J Storbeck; Charles Lefebvre; David Stojdl; Jonathan L Bramson; John C Bell; Yonghong Wan
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

5.  TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

Authors:  Mahiuddin Ahmed; Andres Lopez-Albaitero; Dmitry Pankov; Brian H Santich; Hong Liu; Su Yan; Jingyi Xiang; Pei Wang; Aisha N Hasan; Annamalai Selvakumar; Richard J O'Reilly; Cheng Liu; Nai-Kong V Cheung
Journal:  JCI Insight       Date:  2018-02-22

6.  Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.

Authors:  Timothy T Spear; Yuan Wang; Thomas W Smith; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

7.  T Cell Receptor Engineered Lymphocytes for Cancer Therapy.

Authors:  Meagan R Rollins; Ellen J Spartz; Ingunn M Stromnes
Journal:  Curr Protoc Immunol       Date:  2020-06

8.  Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.

Authors:  Helena M Bijen; Dirk M van der Steen; Renate S Hagedoorn; Anne K Wouters; Linda Wooldridge; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Mol Ther       Date:  2018-02-23       Impact factor: 11.454

9.  Small-molecule inducible transcriptional control in mammalian cells.

Authors:  Aarti Doshi; Fatemeh Sadeghi; Navin Varadarajan; Patrick C Cirino
Journal:  Crit Rev Biotechnol       Date:  2020-08-30       Impact factor: 8.429

10.  T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity.

Authors:  Preeti Sharma; Daniel T Harris; Jennifer D Stone; David M Kranz
Journal:  Cancer Immunol Res       Date:  2019-09-23       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.